US › Healthcare

XOMA Royalty Corporation (XOMA)

US · Healthcare · Biotechnology

$40.170.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$12.3M
Revenue YoY
-22.6%
Net profit
$4.5M
Profit YoY
+88.6%
EPS
$0.17
EPS estimate
$-0.06
Net margin
36.2%

EPS came in at 0.17 against a street estimate of -0.06 — a beat of 414.5%.

Key statistics

Market cap
$710.2M
P/E
25.6
Forward P/E
19.5
P/B
6.29
Book value
$7.79
EPS (TTM)
$1.57
52-week high
$45.22
52-week low
$22.29
50-day MA
$41.95
200-day MA
$33.57
Beta
0.86

Analyst view

Analysts rate XOMA Royalty Corporation a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $39.00.

Shareholding

Insiders
2.33%
Institutions
85.33%

Largest institutional holders

FundStake
Bvf Inc14.65%
Morgan Stanley - Brokerage Accounts9.63%
FMR Inc7.37%
BlackRock Inc3.66%
Woodline Partners LP3.62%
Vanguard Capital Management, LLC3.11%
Opaleye Management Inc1.70%
GW&K Investment Management, LLC1.31%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for XOMA Royalty Corporation — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.